TriSalus Life SciencesTLSI +3.80%29 Return-on-Tangible-Asset is 11.58% as of Mar. 2026. GuruFocus rates TLSI with a GF Score™ of 29/100 and a GF Value™ of $4.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 854 Medical Devices & Instruments companies, TriSalus Life Sciences ranks worse than 84.78% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. TriSalus Life Sciences's annualizedNet Income for the quarter that ended in Mar. 2026 was $6.16 Mil. TriSalus Life Sciences's average total tangible assets for the quarter that ended in Mar. 2026 was $53.16 Mil. Therefore, TriSalus Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 11.58%.
The historical rank and industry rank for TriSalus Life Sciences's Return-on-Tangible-Asset or its related term are showing as below:
TLSI'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -259.28 Med: -132.3 Max: -64.2
Current: -64.2
During the past 5 years, TriSalus Life Sciences's highest Return-on-Tangible-Asset was -64.20%. The lowest was -259.28%. And the median was -132.30%.
TLSI's Return-on-Tangible-Asset is ranked worse than 84.78% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.665
vs TLSI: -64.20
TriSalus Life Sciences (NAS:TLSI) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
TriSalus Life Sciences Return-on-Tangible-Asset Related Terms
TriSalus Life Sciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for TriSalus Life Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences Return-on-Tangible-Asset Chart
TLSI vs TMCI, LAB, SENS: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 11.58% mean?
TriSalus Life Sciences (TLSI) has a Return-on-Tangible-Asset of 11.58% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on TriSalus Life Sciences and its competitors. According to the industry distribution chart, TriSalus Life Sciences ranks #724 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 84.8%.
Is TriSalus Life Sciences' Return-on-Tangible-Asset too high?
TriSalus Life Sciences' current Return-on-Tangible-Asset is 11.58%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.67. TriSalus Life Sciences' value of 11.58% is 1641.4% above this industry median. Based on the distribution chart, TriSalus Life Sciences ranks #724 out of 854 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TriSalus Life Sciences has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Return-on-Tangible-Asset compare to TMCI and LAB?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #724 out of 854 companies for Return-on-Tangible-Asset. This places TriSalus Life Sciences in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.67. TriSalus Life Sciences' value of 11.58% is 1641.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.67, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TriSalus Life Sciences's current Return-on-Tangible-Asset of 11.58% is 1641.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on TriSalus Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current Return-on-Tangible-Asset is 11.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.31, compared to a current price of $3.82 — trading 11.4% below its estimated fair value. The current Return-on-Tangible-Asset is 11.58% and 1641.4% above the Medical Devices & Instruments industry median of 0.67. TriSalus Life Sciences' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Return-on-Tangible-Asset is 11.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be undervalued.
The current stock price of $3.82 is trading 11.4% below its estimated GF Value™ of $4.31.
GuruFocus considers TriSalus Life Sciences to be Modestly Undervalued.
Key valuation signals for TLSI:
Return-on-Tangible-Asset: 11.58%
GF Value™: $4.31 vs. price of $3.82 (11.4% below fair value)
Industry Position: 1641.4% above the Medical Devices & Instruments median (#724 of 854)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
29GF Score
Get the complete analysis for TLSI
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
